DYRKi
DYRKi is an inhibitor of DYRK1 and DYRK1B with IC50 values of 3.7 µM and 90 nM, respectively, which is used as a potent antagonist of Hh/Gli signaling. DYRKi impairs SMO-dependent and SMO-independent oncogenic GLI activity in human medulloblastoma cells. DYRKi is promising for research of HH/GLI-associated cancers.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1640364-04-0
- Fòrmula: C20H13F3N4O2S
- Peso molecular:430.40
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Chemical Information
-
No. CAS 1640364-04-0
-
Peso molecular 430.40
-
Fòrmula C20H13F3N4O2S
-
SMILES
O=C(NC1=NC2=CC(C(F)(F)F)=CC=C2N1)C3=CSC(C4=CC=C5OCCC5=C4)=N3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Kokkorakis N, et al. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy. Pharmaceutics. 2024 Apr 11;16(4):528. [Content Brief]
[2]. Gruber W, et al. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget. 2016 Feb 9;7(6):7134-48. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DYRKi Related Classifications
HY-119607 Related Classifications
Powered by Bioz